Genotype-Directed Phase II Study Of Higher Dose Of Irinotecan In First-Line Metastatic Colorectal Cancer Patients Treated With Folfiri Plus Bevacizumab

Trial Profile

Genotype-Directed Phase II Study Of Higher Dose Of Irinotecan In First-Line Metastatic Colorectal Cancer Patients Treated With Folfiri Plus Bevacizumab

Recruiting
Phase of Trial: Phase II

Latest Information Update: 23 Mar 2017

At a glance

  • Drugs Irinotecan (Primary)
  • Indications Colon cancer
  • Focus Pharmacogenomic; Therapeutic Use
  • Most Recent Events

    • 02 Jun 2015 Study design presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
    • 29 Dec 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrial.gov record.
    • 09 Jul 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top